319 related articles for article (PubMed ID: 34100398)
1. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
[TBL] [Abstract][Full Text] [Related]
2. Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India.
Thota P; Thota A; Medhi B; Sidhu S; Kumar P; Selvan VK; Singh GN
Perspect Clin Res; 2018; 9(1):51-55. PubMed ID: 29430420
[TBL] [Abstract][Full Text] [Related]
3. Development of Pharmacovigilance System in India and Paradigm of Pharmacovigilance Research: An Overview.
Singh P; Vaishnav Y; Verma S
Curr Drug Saf; 2023; 18(4):448-464. PubMed ID: 36200243
[TBL] [Abstract][Full Text] [Related]
4. Pharmacovigilance in India: Present Scenario and Future Challenges.
Kalaiselvan V; Srivastava S; Singh A; Gupta SK
Drug Saf; 2019 Mar; 42(3):339-346. PubMed ID: 30269244
[TBL] [Abstract][Full Text] [Related]
5. Cefixime-associated acute generalized exanthematous pustulosis: Rare cases in India.
Kumar V; Kalaiselvan V; Kumar AP; Saurabh A; Thota P; Sidhu S; Medhi B
Indian J Pharmacol; 2018; 50(4):204-207. PubMed ID: 30505057
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in India.
Kalaivani M; Singh A; Kalaiselvan V
MAbs; 2015; 7(1):276-80. PubMed ID: 25523367
[TBL] [Abstract][Full Text] [Related]
7. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
8. "ADR PvPI" Android mobile app: Report adverse drug reaction at any time anywhere in India.
Prakash J; Joshi K; Malik D; Mishra O; Sachan A; Kumar B; Bhushan S; Kalaiselvan V; Singh GN
Indian J Pharmacol; 2019; 51(4):236-242. PubMed ID: 31571709
[TBL] [Abstract][Full Text] [Related]
9. Public-private partnership (3Ps) in ensuring safe use of medicines: An Indian experience.
Kalaiselvan V; Shukla S; Arora S; Shrivastava TP; Raghuvanshi RS
Front Public Health; 2022; 10():930696. PubMed ID: 36062131
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous Adverse Drug Reaction Monitoring in a Tertiary Care Centre.
Kaur K; Kanwal P; Goyal P; Singh P; Yakhmi S; Jain S; Kaushal S
Curr Drug Saf; 2020; 15(3):215-221. PubMed ID: 32735525
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance Programme of India: Recent developments and future perspectives.
Kalaiselvan V; Thota P; Singh GN
Indian J Pharmacol; 2016; 48(6):624-628. PubMed ID: 28066097
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
[TBL] [Abstract][Full Text] [Related]
13. Current Scenario and Future Prospects of Adverse Drug Reactions (ADRs) Monitoring and Reporting Mechanisms in the Rural Areas of India.
Shukla S; Sharma P; Gupta P; Pandey S; Agrawal R; Rathour D; Kumar Kewat D; Singh R; Kumar Thakur S; Paliwal R; Sulakhiya K
Curr Drug Saf; 2024; 19(2):172-190. PubMed ID: 37132145
[TBL] [Abstract][Full Text] [Related]
14. Status of documentation grading and completeness score for Indian individual case safety reports.
Vivekanandan K; Rishi K; Prasad T; Arunabh T; Singh GN
Indian J Pharmacol; 2015; 47(3):325-7. PubMed ID: 26069373
[TBL] [Abstract][Full Text] [Related]
15. Artificial Intelligence in Pharmacovigilance and COVID-19.
Bhardwaj K; Alam R; Pandeya A; Sharma PK
Curr Drug Saf; 2023; 18(1):5-14. PubMed ID: 35382726
[TBL] [Abstract][Full Text] [Related]
16. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
18. Safety monitoring of local anaesthetic drugs from the perspective of Pharmacovigilance Programme of India.
Kumar P; Kaur I; Kalaiselvan V; Singh A
Indian J Anaesth; 2017 Jul; 61(7):534-537. PubMed ID: 28794523
[TBL] [Abstract][Full Text] [Related]
19. Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring.
Kuemmerle A; Dodoo AN; Olsson S; Van Erps J; Burri C; Lalvani PS
Malar J; 2011 Mar; 10():57. PubMed ID: 21388536
[TBL] [Abstract][Full Text] [Related]
20. Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
Bhushan S; Ray RS; Prakash J; Singh GN
Clin Ther; 2019 Nov; 41(11):2252-2262. PubMed ID: 31543285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
